
Amplifon S.p.A.
Amplifon
Amplifon S.p.A. is an Italian hearing care company headquartered in Milan and founded in 1950. It sells hearing instruments and audiological services through more than 10,000 points of sale in 26 countries across EMEA, the Americas and Asia-Pacific, and employed 15,078 people at 31 December 2025. The company is listed on Borsa Italiana's Euronext Milan under ticker AMP, with a secondary quotation on XETRA under AXNA. Control sits with Ampliter S.r.l., the Holland family holding chaired by Susan Carol Holland, which held 38.69% of issued share capital and 70.09% of voting rights as of May 2026 through a loyalty voting structure. FY2025 revenue was USD 2.81 billion, net income USD 107.3 million, and total assets EUR 3.89 billion against equity of EUR 0.9985 billion. A reserved capital increase of 56 million shares to GN Store Nord A/S, approved by shareholders in October 2026, will dilute Ampliter to 32.07% of capital and 63.69% of voting rights once the EUR 2.3 billion GN Hearing acquisition closes.
Strengths: Retail density is the core asset: over 10,000 points of sale give Amplifon a fitting and aftercare network that device manufacturers cannot replicate quickly, and the multi-brand portfolio (Amplifon, Miracle-Ear, GAES, Beter Horen, Bay Audio, Attune, Dilworth) lets it address different reimbursement regimes with local names. Revenue grew from USD 2.21 billion in FY2021 to USD 2.81 billion in FY2025, a 27% increase that outpaced most hearing-aid wholesale markets. The EUR 2.3 billion GN Hearing purchase converts Amplifon from a pure retailer into a vertically integrated manufacturer and retailer, with management targeting EUR 60–80 million of run-rate EBITDA synergies. The loyalty voting structure keeps the Holland family's 70.09% voting position intact through the transaction, providing strategic continuity.
Weaknesses: Profitability is thin and deteriorating: net income fell from USD 191.0 million in FY2022 to USD 107.3 million in FY2025, a 44% decline, on revenue that rose over the same period. Equity contracted from EUR 1.1502 billion in FY2024 to EUR 0.9985 billion in FY2025, leaving leverage-sensitive room for the GN deal. The acquisition carries integration risk at scale, and the EUR 600 million senior unsecured notes proposed in November 2026 were assigned a BB+ rating, below investment grade. Operational exposure is also visible: Amplifon Americas disclosed a security incident affecting patient and member data in November 2026, and the 56-million-share issuance to GN dilutes existing holders and reduces the family's capital stake to 32.07%.
Read MoreShow Less
Amplifon S.p.A. is an Italian hearing care company headquartered in Milan and founded in 1950. It sells hearing instruments and audiological services through more than 10,000 points of sale in 26 countries across EMEA, the Americas and Asia-Pacific, and employed 15,078 people at 31 December 2025. The company is listed on Borsa Italiana's Euronext Milan under ticker AMP, with a secondary quotation on XETRA under AXNA. Control sits with Ampliter S.r.l., the Holland family holding chaired by Susan Carol Holland, which held 38.69% of issued share capital and 70.09% of voting rights as of May 2026 through a loyalty voting structure. FY2025 revenue was USD 2.81 billion, net income USD 107.3 million, and total assets EUR 3.89 billion against equity of EUR 0.9985 billion. A reserved capital increase of 56 million shares to GN Store Nord A/S, approved by shareholders in October 2026, will dilute Ampliter to 32.07% of capital and 63.69% of voting rights once the EUR 2.3 billion GN Hearing acquisition closes.
Strengths: Retail density is the core asset: over 10,000 points of sale give Amplifon a fitting and aftercare network that device manufacturers cannot replicate quickly, and the multi-brand portfolio (Amplifon, Miracle-Ear, GAES, Beter Horen, Bay Audio, Attune, Dilworth) lets it address different reimbursement regimes with local names. Revenue grew from USD 2.21 billion in FY2021 to USD 2.81 billion in FY2025, a 27% increase that outpaced most hearing-aid wholesale markets. The EUR 2.3 billion GN Hearing purchase converts Amplifon from a pure retailer into a vertically integrated manufacturer and retailer, with management targeting EUR 60–80 million of run-rate EBITDA synergies. The loyalty voting structure keeps the Holland family's 70.09% voting position intact through the transaction, providing strategic continuity.
Weaknesses: Profitability is thin and deteriorating: net income fell from USD 191.0 million in FY2022 to USD 107.3 million in FY2025, a 44% decline, on revenue that rose over the same period. Equity contracted from EUR 1.1502 billion in FY2024 to EUR 0.9985 billion in FY2025, leaving leverage-sensitive room for the GN deal. The acquisition carries integration risk at scale, and the EUR 600 million senior unsecured notes proposed in November 2026 were assigned a BB+ rating, below investment grade. Operational exposure is also visible: Amplifon Americas disclosed a security incident affecting patient and member data in November 2026, and the 56-million-share issuance to GN dilutes existing holders and reduces the family's capital stake to 32.07%.
Listed market data
2 Listings · weeklyHistory →- Market cap
- $3.5 B
- Share price
- EUR 11.86
- 1Y change
- -12.9%
- Recent change
- +0.3%
- Since first close
- +660.3%
- Revenue (TTM)
- $2.8 B
11-13 → 11-16
from 2001-10
Financial history
Full market history- 2026-11EUR 11.86$3.5 B+6.2%
- 2026-10EUR 11.17$3.3 B-7.7%
- 2026-09EUR 12.10$3.6 B-0.1%
- 2026-08EUR 12.11$3.6 B-0.3%
- 2026-07EUR 12.15$3.6 B+28.2%
- 2026-06EUR 9.48$2.8 B-12.1%
- 2026-05EUR 10.78$3.2 B+14.7%
- 2026-04EUR 9.40$2.8 B0.0%
- 2026-03EUR 9.40$2.8 B-28.7%
- 2026-02EUR 13.18$3.9 B-3.1%
- 2026-01EUR 13.59$4 B-1.2%
- 2025-12EUR 13.75$4.1 B—
Ownership & Control
Latest available filings- Controlling entity
- Ampliter S.r.l. (Holland Family) — 38.69%
- Company type
- Company
- Insiders
- 35.01%
- Institutions
- 22.39%(170 holders)
- Free float
- 38.47%
Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.
In the press
All coverage →4 latest headlines- Amplifon Americas Discloses Security Incident Affecting Patient and Member Datahearingreview.com2026-11-10
- Amplifon SpA's Proposed EUR 600 Million Senior Unsecured Notes Assigned 'BB+' Ratingspglobal.com2026-11-09
- Amplifon Receives European Commission Approval for the Acquisition of GN's Hearing Aid Businesscorporate.amplifon.com2026-11-06
- Amplifon Shareholders' Meeting Approves Share Capital Increase Reserved for GN in Connection with Acquisition of GN Hearingcorporate.amplifon.com2026-10-29
• Company-owned clinics and shop-in-shops selling digital hearing instruments and fitting services
• Operates across EMEA as the group's principal consumer-facing brand
• Anchors the 10,000-plus point-of-sale network reported at FY2025
Miracle-Ear – North American retail franchise and corporate network
• US-focused hearing aid retail brand within the Americas region
• Supported by Amplifon Hearing Health Care for insurance and managed-care channels
• One of several local brands used to match US reimbursement and consumer expectations
GAES – Iberian and Latin American retail chain
• Hearing care clinics serving Spain, Portugal and Latin American markets
• Extends the group's Spanish-language and southern-European footprint
• Part of the multi-brand structure that tailors naming to local markets
Beter Horen and Minisom – Benelux and European retail operations
• Beter Horen covers the Dutch hearing care market
• Minisom adds further European retail capacity under a local brand
• Demonstrates the group's pattern of acquiring and retaining established local names
Bay Audio, Bay Audiology, Attune Hearing and Dilworth Hearing – Asia-Pacific retail and diagnostics
• Australian and New Zealand clinic networks covering retail and audiology services
• Attune Hearing and Dilworth Hearing add diagnostic and clinical depth
• Provide the APAC leg of the 26-country operating footprint
AmplifonX – digital and technology R&D hub
• Milan-based unit focused on digital hearing care tools and remote service models
• Supports clinic productivity and the Fit4Growth optimization programme
• Sits alongside the global headquarters in Milan
GN Hearing integration – vertically integrated manufacturing
• EUR 2.3 billion acquisition approved by the European Commission in November 2026
• Adds hearing instrument manufacturing to a historically retail-led model
• Target of EUR 60–80 million in run-rate EBITDA synergies
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2025 | $2.8 B | $107 M |
| 2024 | $2.5 B | $151 M |
| 2023 | $2.5 B | $171 M |
| 2022 | $2.3 B | $191 M |
| 2021 | $2.2 B | $179 M |
Annual results from company filings (SEC XBRL), converted to US dollars.
Quick Facts
Headquarters
Founded
Employees
Market cap
Factories
Presence
Listing
Categories
Related
Similar listed companies
- Thermo Fisher Scientific Inc.· $257 B
- Siemens AG· $235 B
- Danaher Corporation· $164 B
- ABB Ltd· $150 B
- EssilorLuxottica· $93.1 B
- Emerson Electric Co.· $92.4 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website
